ClinicalTrials.gg
RecruitingNCT07599410Updated Jul 23, 2026

A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus

A Phase 2 interventional study of HRS9531 Tablet and HRS9531 Tablet in T2DM, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of the trial is to investigate the efficacy and safety of HRS9531 tablets versus placebo in participants with type 2 diabetes mellitus who failed to achieve adequate glycemic control on lifestyle intervention alone or on a stable dose of metformin. This study will last 20 weeks.

02

Conditions studied

  • T2DM
03

In context

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 70 years on the day of signing the form;
  2. Have a documented history of type 2 diabetes mellitus for at least 6 months at screening, diagnosed according to the criteria in Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2024 Edition);
  3. between 7.5% and 10.5% at screening;
  4. Have received lifestyle intervention alone for at least 8 weeks, or stable metformin monotherapy for at least 8 weeks prior to screening. Stable treatment is defined as no change in daily drug dosage, with no planned modifications to the regimen during the entire trial period;
  5. Fasting plasma glucose ≤ 15 mmol/L;
  6. (BMI) between 20.0 kg/m² and 40.0 kg/m² at screening;
  7. Voluntarily sign the informed consent form before the trial, fully understand the trial content, procedures and potential adverse reactions, and be able and willing to comply with protocol requirements to complete the study;
  8. Have no fertility plans from the signing of the informed consent form until 2 months after the last dose, and agree to use highly effective measures as specified in the protocol.methods.

Exclusion criteria

Exclusion Criteria:

  1. Participants with relevant abnormal test results at screening.
  2. Participants with abnormal findings on (ECG) that, in the investigator's opinion, may compromise subject safety.
  3. Participants with poorly controlled blood pressure.
  4. Participants diagnosed with or suspected of having type 1 diabetes, specific types of diabetes, or secondary diabetes.
  5. Participants who experienced acute diabetic complications within 6 months prior to screening.
  6. Participants who experienced severe hypoglycemic events or recurrent hypoglycemic events within 6 months prior to screening.
  7. Participants with severe chronic diabetic complications at screening, or non-proliferative diabetic retinopathy requiring treatment during the trial.
  8. Participants with a past or known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
  9. Participants with a past or known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treatment requiring gallbladder disease.
  10. Participants with a past history of significant gastrointestinal diseases (such as severe diabetic gastroparesis, gastric outlet obstruction, inflammatory bowel disease, active ulcer, etc.), or who have undergone gastrointestinal surgery (excluding gastrointestinal polypectomy and appendectomy), or who are taking long-term medications that directly affect gastrointestinal motility.
  11. Participants with a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening.
  12. Participants with known or suspected depression, bipolar disorder, suicidal ideation, schizophrenia, or other severe psychiatric disorders; or participants who are mentally incompetent, have language barriers, are unable to fully understand the trial protocol, or are unwilling to cooperate with study site staff.
  13. Participants with a history of malignant tumor within 5 years prior to screening, except for cured localized cancers such as localized basal cell carcinoma of the skin, cervical carcinoma in situ, and prostate carcinoma in situ.
  14. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the trial.
  15. Any other conditions that, in the investigator's judgment, render the subject unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HRS9531 Tablet

    Drug: HRS9531 Tablet

  • Experimental
    Treatment group B: HRS9531 Tablet

    Drug: HRS9531 Tablet

  • Experimental
    Treatment group C: HRS9531 Tablet

    Drug: HRS9531 Tablet

  • Experimental
    Treatment group D: HRS9531 Tablet

    Drug: HRS9531 Tablet

  • Experimental
    Treatment group E: HRS9531 Tablet

    Drug: HRS9531 Tablet

  • Placebo comparator
    Treatment group F:Placebo

    Drug: HRS9531 Tablet placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in glycated hemoglobin (HbA1c) relative to baseline

    Time frame: Week 20.

Secondary outcomes

  1. Percentage of participants achieving HbA1c < 7.0%

    Time frame: Week 20

  2. Percentage change in fasting body weight relative to baseline

    Time frame: Week 20

  3. Change in fasting plasma glucose (FPG) relative to baseline

    Time frame: Week 20

  4. Incidence of hypoglycemic events across all groups

    Time frame: Week 20

  5. Incidence of adverse events (AEs) across all groups

    Time frame: Week 20

07

Study locations

2 of 2 sites recruiting
  • Beijing Chaoyang Hospital, Capital Medical University
    Beijing, Beijing Municipality 100020, China
    Recruiting
    • Guang Wang · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
    • Xinguo Hou · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 20, 2026
StartActual
Jul 14, 2026
Primary completionEst.
May 2027
CompletionEst.
Jul 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599410
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Jul 14, 2026
Primary completion
May 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Junmeng Shi
Contact
junmeng.shi.js12@hengrui.com
17721288226

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS9531

Start the discussion